Krystal Biotech
KRYS | NASDAQ
$297.90
-$7.33 (-2.40%)
At close: Nov 16, 2026, 4:00 PM ET
$297.90
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Krystal Biotech Company Profile
Company profile explainedCompany Profile
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Krish S. Krishnan | Founder, Chairman, President & Chief Executive Officer |
| Christine Wilson | Senior VP & Head of US Commercial |
| David Chien | Senior Vice President of Clinical Development |
| John Karakkal | Vice President of North American Sales & Marketing |
| John Thomas | EVP, General Counsel & Corporate Secretary |
| Josh Suskin | Senior Director & Head of US Human Resources |
| Kathryn A. Romano | Executive Vice President & Chief Accounting Officer |
| Laurent Goux | Executive VP & Head of International |
| Stephane Paquette | Senior Vice President of Corporate Development |
| Suma Krishnan | Founder, President of R&D and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 15, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
Krystal Biotech
| Country | United States |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 295 |
| CEO | Krish S. Krishnan |
Contact Details
2100 Wharton Street Pittsburgh,
Pennsylvania 15203 United States
Stock Details
| Ticker Symbol | KRYS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001711279 |
| CUSIP Number | 501147102 |
| ISIN Number | US5011471027 |
| SIC Code | 2836 |
Recent News
- 15 days ago / benzinga.comKrystal Biotech Analyst Says Stock Weakness 'Overblown'
- 15 days ago / seekingalpha.comKrystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call Transcript
- 15 days ago / zacks.comKrystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates
- 15 days ago / marketbeat.comKrystal Biotech Q3 Earnings Call Highlights
- 15 days ago / globenewswire.comKrystal Biotech Announces Third Quarter 2026 Financial and Operating Results
- 22 days ago / zacks.comAnalysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out for
- 26 days ago / globenewswire.comKrystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
- 1 month ago / zacks.comKRYS Reports Positive Early Data for KB113 in Gorlin Syndrome
- 1 month ago / globenewswire.comKrystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
- 1 month ago / seekingalpha.comKrystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value
Add to Watchlist
Select watchlists to add or remove KRYS